Notably, we observed same expression trends in a LNCaP xenograft tumor dataset44, where LNCaP cell-derived xenografts relapsed from treatment with second generation androgen receptor targeted therapy, enzalutamide, and became NEPC (Fig. 7e). Here, AR is linked to neoplasm.